Among @ randomized patients there were no statistically significant differences between regimens using @-FU vs capecitabine in three-year local-regional tumor event rates ( @ % vs @ % ) , @-year DFS ( @ % vs @ % ) , or @-year OS ( @ % vs @ % ) ; or for oxaliplatin vs no oxaliplatin for the three endpoints of local-regional events , DFS , and OS ( @ % vs @ % , @ % vs @ % , and @ % vs @ % ) .